← Back to Search

Anti-androgen

VERU-100 for Prostate Cancer (VERU-100 Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Veru Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28 and day 91
Awards & highlights

Summary

This trial will test the feasibility of using VERU-100 to lower testosterone levels in men with advanced prostate cancer.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28 and day 91
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 and day 91 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of men with total testosterone at <50 ng/dL by day 28
Secondary outcome measures
Total testosterone below 20ng/dL levels on VERU-100

Trial Design

1Treatment groups
Experimental Treatment
Group I: VERU-100 at various dosesExperimental Treatment1 Intervention
2 ml, 2.5 ml, 3 ml, 3.5 ml of VERU-100

Find a Location

Who is running the clinical trial?

Veru Inc.Lead Sponsor
10 Previous Clinical Trials
728 Total Patients Enrolled
BernetteStudy ChairVeru Inc.
~6 spots leftby Jul 2025